The hemoflagellate protozoa of the family Trypanosomatidae are the causative agents of tropical diseases such as human African sleeping sickness (*Trypanosoma brucei* gambiense, *T. brucei* rhodesiense), Chagas' disease (South American trypanosomiasis, *Trypanosoma cruzi*) and the visceral, cutaneous and mucocutaneous manifestations of leishmaniasis (e.g., *Leishmania donovani*, *Leishmania tropica*, *Leishmania braziliensis*). According to world health organization African trypanosomiasis was estimated to cause 48,000 deaths and a disease burden of 1.5 million disability-adjusted life years (DALYs) annually; Chagas' disease, 14,000 deaths and a disease burden of 0.7 million DALYs annually; leishmaniasis, 51,000 deaths and a disease burden of 2.1 million DALYs annually. Recently drug discovery program directed toward leishmaniasis, malaria, Chagas disease and sleeping sickness has increased sharply and not only because they are major killing diseases, but also because disease control becomes more difficult due to a number of factors that limit the utility of current drugs such as high cost, poor compliance, drug resistance, low efficacy and poor safety. The development of new chemotherapeutic agents for the treatment of these parasitic diseases has been hindered due to lack of interest shown by top innovator pharmaceutical companies, which might be due to low profitability in this domain as poor are more sufferer of these disease.\[[@ref1][@ref2][@ref3][@ref4]\]

The present review focuses on the major human diseases caused by trypanosomal and leishmanial infections and inhibitors of tryanothione reductase as potential targets for designing chemotherapeutic agents against these diseases. [Table 1](#T1){ref-type="table"} gives an outline of the major human trypanosomiasis and leishmaniasis with their global annual disease burdens in terms of DALY The chemical structures of various antitrypnosomal and antileishmanial agents are presented as [Figure 1](#F1){ref-type="fig"}.

###### 

The major trypanosomiasis and leishmaniasis and their causative agents current treatments
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There are several targets in these parasites through which drug or an investigational molecules act and some of these targets includes deoxyribonucleic acid (DNA) topoisomerases, Ergosterol biosynthesis, Purine salvage pathway, trypanothione reductase (TryR), microtubule assembly inhibitor etc.\[[@ref5]\] Among all the targets known for trypanosomes and *Leishmania*, TryR has gained a lot of attention as a potential target for discovering a new antiparasitic drug for the treatment of human African sleeping sickness caused by *T. brucei* gambiense, *T. brucei* rhodesiense, Chagas' disease (South American trypanosomiasis, *T. cruzi*) and the visceral, cutaneous and mucocutaneous manifestations of leishmaniasis (e.g., *L. donovani*, *L. tropica*, *L. braziliensis*).

As potential drug target in trypanosomes and *Leishmania*, TryR has been identified through the discovery of a fundamental difference between the redox defense system of the trypanosomal/leishmanial parasite and the infected host. The mammalian redox defense system is based on glutathione (l-g-glutamyl-l-cysteinylglycine) and glutathione disulfide reductase (glutathione reductase (GR); EC 1.6.4.2), this system is replaced in trypanosomatids by an analogous system based on trypanothione (N, N-bis \[glutathionyl\] spermidine) and trypanothione disulfide reductase (TryR; EC 1.6.4.8). The structures of the disulfide substrates for TryR and GR are illustrated in [Figure 2](#F2){ref-type="fig"}. TryR is a nicotinamide adenine dinucleotide phosphate-oxidase-dependent flavoprotein oxidoreductase which maintains an intracellular reducing environment by the recycling of trypanothione disulfide T\[S\]~2~ to its dithiol T\[SH\]~2~ form. Trypanothione is oxidized back to T\[S\]~2~ following reaction with potentially damaging radicals and oxidants generated by aerobic metabolism and by host macrophages. By maintaining a high intracellular ratio of T\[SH\]~2~ the TryR redox cycle is a primary line of defense for these parasites against respiratory burst responses from the mammalian host. The trypanothione system is necessary for protozoan survival because the dithiol trypanothione is required for the synthesis of DNA precursors, the homeostasis of ascorbate, the detoxification of hydroperoxides and the sequestration/export of thiol conjugates. Moreover, the majority of peroxidases that eliminate the reactive oxygen species generated in the aerobic metabolism are trypanothione dependent. Disabling the function of TryR in *Leishmania* and *T. brucei* has been shown to markedly increase the parasites' sensitivity to oxidative stress.
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T\[S\]~2~ differs from glutathione disulfide (GSSG) by the presence of a spermidine cross-link between the two glycyl carboxyl groups \[compare GSSG and T\[S\]~2~ in [Figure 2](#F2){ref-type="fig"}\]. Due to structural and charge differences between T\[S\]~2~ and GSSG, TryR and GR are mutually exclusive with respect to substrate specificity. Thus the essential requirement of TryR in trypanosomal/leishmanial parasite and its absence in host metabolism make it an attractive therapeutic target for designing specific inhibitor. In the preceding section we have tried to compile various tricyclic compounds, which have shown potent inhibiting activity against TryR.\[[@ref6][@ref7][@ref8]\]

Tricyclic trypanothione reductase (TryR) inhibitors {#sec2-1}
===================================================

Knowing the fact that both TryR and GR has exclusive substrate specificity, various molecules have been explored as inhibitors of TryR which includes hydrophobic linear polyamine derivatives and the naturally occurring bis (tetrahydrocinnamoyl) spermine, Ponasik *et al*.\[[@ref9]\]

To further address the need for new compounds and new compound classes, Richardson *et al*.\[[@ref10]\] initiated screening of 1266 pharmacologically active compounds from the Sigma-Aldrich LOPAC1280 library. These compounds were screened against TryR and the top hits counter-screened against GR and live *T. brucei* parasites, yielding the IC values, selectivity for TryR over GR and antiparasitic activity. Among all the 1266 compounds from Sigma-Aldrich LOPAC1280 library, several tricyclic derivatives were identified as a potent inhibitor TryR \[[Figure 3](#F3){ref-type="fig"}\].
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Recently, lunarine a spermidine-based macrocyclic alkaloid \[[Figure 4](#F4){ref-type="fig"}\] has been identified as a competitive, time-dependent inhibitor of TryR. Lunarine is composed of a spermidine chain with the terminal nitrogen atoms forming amide linkages with two α, β-unsaturated carboxylic acid functions disposed upon an unusual 3-oxohexahydrodibenzofuranyl tricyclic scaffold.\[[@ref11]\]
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A study done by Hamilton *et al*.\[[@ref12]\] presented a possible mechanism for this time dependent inhibition, which involves the covalent modification of a redox-active cysteine residue in the active site of TryR (C53) by conjugate addition to one of these unsaturated amide moieties in the lunarine macrocycle \[[Figure 5](#F5){ref-type="fig"}\]. This was supported by both the requirement for the enzyme in its reduced form and the presence of a potential Michael acceptor unit in the inhibitor.
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The Hamilton *et al*.\[[@ref13]\] further explored this approach by preparing some benzofuranyl-based acyclic bis-polyamine analogues (1-5) of lunarine. In their approach they removed skew boat cyclohexanone moiety of lunarine leaving a planar bicyclic benzofuranyl scaffold. The acyclic bis-polyamine derivatives were chosen since bis-polyamine functionalized disulfides such as the naturally occurring N^1^-glutathionylspermidine disulfide and the synthetic bis-dimethylaminopropyl- and bis-N-methylpiperazinyl amides of Ellman\'s reagent (DTNB) are known TryR substrates. These three polyamine chains were chosen for functionalisation of a 3, 5-disubstituted benzofuranyl template to give potential inhibitors (1-5).

In their series of compounds the bis-polyaminoacrylamide derivatives (1-3) were shown to be competitive inhibitors, but only the bis-4-methyl-piperazin-1-yl-propylacrylamide derivative 3 displayed time-dependent activity. Analysis of *in vitro* activity showed that these compounds were simple competitive inhibitors of TryR, with respect to T\[S\]~2~. The starting material 4, 5 and 6 which do not have polyamine side chain were also evaluated for enzyme inhibitory activity against TryR. It was observed that due to the absence of any polyamine side chains, neither the diester 6 nor the diacid 4 showed any inhibitory activity towards TryR at 100 μM concentrations.

Bonnet *et al*.\[[@ref14]\] designed and synthesized a series of symmetrical substituted 1,4-bis (3-aminopropyl) piperazines derivatives. The compounds were prepared by reacting 1,4-bis (3-aminopropyl) piperazine with various aldehydes via reductive amination. All compounds were tested for their inhibitory potency towards TryR from *T. cruzi* and their trypanocidal effects upon *T. cruzi* trypomastigote as well as for their trypanocidal effect upon *T. brucei* trypomastigote stage. They also studied cytotoxicity toward human MRC-5 cells (diploid embryonic lung cell line). Their study revealed that in the aromatic series the most potent TR inhibition was observed for polyphenyl derivatives 7 and 8 (IC~50~ of 32 and 28 μM) respectively. These two compounds showed 100% Inhibition on *T. brucei* at a concentration of 6.3 and 3.1 μM.

A study done by Chibale *et al*.\[[@ref15]\] reported design and synthesis of 9, 9-dimethylxanthene derivatives (9-14) as potential inhibitor of TR. They designed target compounds in which 9, 9-dimethylxanthene ring was exploited as an aromatic hydrophobic tricyclic moiety that bears resemblance to the aromatic hydrophobic tricyclic moieties found in other tricyclic compounds already reported as competitive inhibitors of TR, where the tricyclic moiety binds in the hydrophobic pocket involved in recognition of the spermidine moiety of trypanothione disulfide, the substrate for TR. Moreover, in 9, 9-dimethylxanthene system potential multiple sites are provided by chemically reactive 2, 7 and 4, 5 positions for introducing chemical diversity. Apart from these functions, they also introduced terminal tertiary amino group (exemplified by the dimethylamino group) into compounds (9-14) to provide a positive charge which has been shown to favor TryR over GR, the closest related host enzyme. Thorough analysis of results of TryR inhibitions study \[[Table 2](#T2){ref-type="table"}\], it was found that compounds (9-11) bearing either one (10) or no methylene spacer (9 and 11) between the tricyclic moiety and the secondary nitrogen atom generally show weaker inhibition of TR compared to derivatives with two or three carbon methylene spacer (12, 13 and 14) \[[Figure 6](#F6){ref-type="fig"}\].
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Percentage inhibition of TryR and ED~50~ of compounds (9-14)
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They concluded that within the series of compounds (9-15), there is no clear correlation between potency as inhibitors of TR and the *in vitro* antiparasitic activities and that there is no apparent single structural feature controlling *in vitro* antiparasitic activities.

In another study by Chibale *et al*.\[[@ref16]\] had shown that chemical structures of agents which increase accumulation and/or reverse chloroquine (CQ) resistance reveals the importance of a hydrophobic group and a protonatable nitrogen and incidentally these are the same chemical features known to be important for potent and selective against TR inhibitor. This was exemplified in the antimalarial acridine quinacrine and tricyclic antidepressants promazine and clomipramine. A wide variety of structurally diverse drugs (including Mepacrine, Promazine and clomipramine) have also been described as CQ resistance reversal agents.

Based on this observation it was envisaged by Chibale *et al*. that these tricyclic could be utilized as dual purpose scaffolds for the discovery and development of CQ resistance reversal agents and inhibitors of TryR. They designed and developed a series of xanthenes derivatives as potential TR inhibitor. All the tested compounds showed weak TR inhibitory activity against *T. cruzi* TryR. Among the all derivatives of xanthenes, compound 16 showed highest TryR inhibitory activity of IC~50~ of 35.7 μM and intrinsic antimalarial activity of IC~50~ = 1.748 μM.

A series of sulfonamide and urea derivatives of quinacrine with varying methylene spacer lengths have been tested for inhibition of TryR and for activity *in vitro* against strains of the parasitic protozoa *Trypanosoma*, *Leishmania* and Plasmodium by Kelly *et al*.\[[@ref17]\] The results of the studies revealed \[[Table 3](#T3){ref-type="table"}\] that these derivatives were superior inhibitors of TryR relative to quinacrine with the best compound being 40 times more potent. Results of their studies revealed that sulfonamide derivatives were more active than urea in inhibiting TryR and this trend of activity did not correlate with the *in vitro* activities against *L. donovani*, *T. cruzi*, and *T. brucei*.
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*In vitro* sensitivity of the parasite to quinacrine analogue (17-19) and (20-23)
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Girault *et al*.\[[@ref18]\] designed and optimized various bis (2-aminodiphenylsulfides) derivatives and tested for inhibitory activity against TryR from *T. cruzi*. In the series bis (2-aminodiphenylsulfides) compounds possessing three side chains were synthesized and various moieties were introduced at the end of the third side chain, including acridinyl or biotinyl moieties for fluorescent labeling studies. The results of the TR inhibition screening showed that most potent inhibitor (24) with IC~50~ = 200 nM, whereas the tricyclic derivatives (25) exhibited IC~50~ of 250 nM. All the compounds were also tested *in vitro* upon *T. cruzi* and *Leishmania* infantum amastigotes, upon *T. brucei* trypomastigotes.

In order to provide improved tricyclic derivatives as an inhibitor of TryR, Richardson *et al*.\[[@ref10]\] have reported structural modification of Prochlorperazine which shown IC~50~ of 7.46 μM against TryR. They prepared a derivative having additional propylbenzene ring on piperazine moiety of Prochlorperazine and found 10 fold increase in IC~50~ against TryR (IC~50~ = 0.75 μM).

Conclusion {#sec1-2}
==========

The enzyme TryR from trypanosomal and leishmanial parasites meets most of the ideal features as a drug target needed for developing a potent and specific inhibitor for treating infections caused by trypanosomal and leishmanial parasites. Of various class of compounds developed as an inhibitor of TryR, tricyclic derivatives have come up with potential to be further exploited as the drug candidate for the treatment of trypanosomiasis and Leishmaniasis. Although a lot research work has been done to provide tricyclic based derivatives as future therapeutic agents against these parasitic diseases, but yet none of tricyclic agent is able to reach at the level of approval as an effective therapy for trypanosomiasis and Leishmaniasis.
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